GNI looks to begin Chinese trials with pirfenidone for diabetic nephropathy
This article was originally published in Scrip
Executive Summary
The wholly owned Shanghai Genomics subsidiary of the Japan-based venture GNI has applied to begin the clinical development in China of its lead product, pirfenidone, for the additional indication of diabetic nephropathy.